Documenti full-text disponibili:
![Varignani_Giulia_tesi.pdf [thumbnail of Varignani_Giulia_tesi.pdf]](https://amsdottorato.unibo.it/style/images/fileicons/application_pdf.png) |
Documento PDF (English)
- Accesso riservato fino a 14 Giugno 2029
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (6MB)
| Contatta l'autore
|
Abstract
DNA double-strand break repair is essential for genome stability and represents a major vulnerability in cancers with homologous recombination (HR) defects. RAD52, a conserved DNA annealing protein, is a promising synthetic-lethal target in BRCA-deficient tumors, where it becomes essential for cell survival. However, its molecular role and the development of effective inhibitors remain incompletely understood.
This PhD project addressed these challenges through two complementary objectives: elucidating the RAD51–RAD52 interaction and identifying novel RAD52 inhibitors based on small molecules and DNA aptamers.
Human recombinant RAD52 and RAD51 proteins were expressed and purified, and several biochemical approaches were explored to stabilize the RAD51–RAD52 complex for structural studies. Although a stable complex was not obtained, this work established optimized protein-production pipelines and identified key parameters for future structural investigations aimed at uncovering druggable protein–protein interfaces.
To discover RAD52 inhibitors, structure-based virtual screening was performed using high-resolution structural models. Two compounds, ARN8872 and ARN4903, were identified as RAD52 binders. NMR spectroscopy and microscale thermophoresis demonstrated that ARN8872 binds the RAD52 N-terminal domain with micromolar affinity. The compound also showed modest selectivity for specific RAD52 oligomeric states and was advanced for medicinal-chemistry optimization.
As an alternative strategy, DNA aptamers targeting RAD52 DNA-binding regions were computationally designed and characterized using complementary biophysical assays. Four aptamers bound RAD52 with nanomolar affinity and inhibited its single-strand annealing activity in vitro. Cellular assays showed selective cytotoxicity in BRCA2-deficient cancer cells, consistent with a synthetic-lethal mechanism. Dynamic light scattering and cryo-electron microscopy revealed that the most potent aptamer, Apt1, disrupts RAD52 oligomeric rings, providing the first visualization of destabilized human RAD52 assemblies in vitro.
Overall, this work advances the understanding of RAD52 biology and establishes complementary therapeutic strategies for targeting HR-deficient cancers.
Abstract
DNA double-strand break repair is essential for genome stability and represents a major vulnerability in cancers with homologous recombination (HR) defects. RAD52, a conserved DNA annealing protein, is a promising synthetic-lethal target in BRCA-deficient tumors, where it becomes essential for cell survival. However, its molecular role and the development of effective inhibitors remain incompletely understood.
This PhD project addressed these challenges through two complementary objectives: elucidating the RAD51–RAD52 interaction and identifying novel RAD52 inhibitors based on small molecules and DNA aptamers.
Human recombinant RAD52 and RAD51 proteins were expressed and purified, and several biochemical approaches were explored to stabilize the RAD51–RAD52 complex for structural studies. Although a stable complex was not obtained, this work established optimized protein-production pipelines and identified key parameters for future structural investigations aimed at uncovering druggable protein–protein interfaces.
To discover RAD52 inhibitors, structure-based virtual screening was performed using high-resolution structural models. Two compounds, ARN8872 and ARN4903, were identified as RAD52 binders. NMR spectroscopy and microscale thermophoresis demonstrated that ARN8872 binds the RAD52 N-terminal domain with micromolar affinity. The compound also showed modest selectivity for specific RAD52 oligomeric states and was advanced for medicinal-chemistry optimization.
As an alternative strategy, DNA aptamers targeting RAD52 DNA-binding regions were computationally designed and characterized using complementary biophysical assays. Four aptamers bound RAD52 with nanomolar affinity and inhibited its single-strand annealing activity in vitro. Cellular assays showed selective cytotoxicity in BRCA2-deficient cancer cells, consistent with a synthetic-lethal mechanism. Dynamic light scattering and cryo-electron microscopy revealed that the most potent aptamer, Apt1, disrupts RAD52 oligomeric rings, providing the first visualization of destabilized human RAD52 assemblies in vitro.
Overall, this work advances the understanding of RAD52 biology and establishes complementary therapeutic strategies for targeting HR-deficient cancers.
Tipologia del documento
Tesi di dottorato
Autore
Varignani, Giulia
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
RAD52
Synthetic lethality
BRCA2 deficiency
DNA repair
Small-molecule inhibitors
DNA aptamers
Targeted cancer therapy
Protein–protein interactions
Cryo-EM
Data di discussione
3 Luglio 2026
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Varignani, Giulia
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
RAD52
Synthetic lethality
BRCA2 deficiency
DNA repair
Small-molecule inhibitors
DNA aptamers
Targeted cancer therapy
Protein–protein interactions
Cryo-EM
Data di discussione
3 Luglio 2026
URI
Gestione del documento: